4D Molecular Therapeutics Files 8-K on Board and Compensation Changes
Ticker: FDMT · Form: 8-K · Filed: Nov 17, 2025 · CIK: 1650648
| Field | Detail |
|---|---|
| Company | 4d Molecular Therapeutics, INC. (FDMT) |
| Form Type | 8-K |
| Filed Date | Nov 17, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $520,000, $100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
TL;DR
4D Molecular Therapeutics filed an 8-K on Nov 17, 2025, reporting board and exec comp changes.
AI Summary
On November 17, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the election of new directors and potential adjustments to compensatory arrangements for certain officers, though specific details on individuals and amounts are not provided in this summary section of the filing.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, which are important for investors to monitor.
Risk Assessment
Risk Level: low — This filing is routine and reports on corporate governance matters without immediate financial implications.
Key Players & Entities
- 4D Molecular Therapeutics, Inc. (company) — Registrant
- November 17, 2025 (date) — Date of Report
FAQ
What specific items are being reported in this 8-K filing by 4D Molecular Therapeutics, Inc.?
The 8-K filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on November 17, 2025.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is 4D Molecular Therapeutics, Inc.
In which state was 4D Molecular Therapeutics, Inc. incorporated?
4D Molecular Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address of 4D Molecular Therapeutics, Inc.?
The principal executive office address is 5858 Horton Street #455, Emeryville, California, 94608.
Filing Stats: 899 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2025-11-17 06:05:25
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share FDMT Nasdaq Glo
- $520,000 — er things, (i) an annual base salary of $520,000 per year, (ii) a discretionary annual p
- $100,000 — sign-on bonus in an aggregate amount of $100,000, payable in two equal installments, wit
Filing Documents
- d14139d8k.htm (8-K) — 27KB
- 0001193125-25-283861.txt ( ) — 139KB
- fdmt-20251117.xsd (EX-101.SCH) — 3KB
- fdmt-20251117_lab.xml (EX-101.LAB) — 18KB
- fdmt-20251117_pre.xml (EX-101.PRE) — 11KB
- d14139d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 4D MOLECULAR THERAPEUTICS, INC. Date: November 17, 2025 By: /s/ David Kirn, M.D. David Kirn, M.D. Chief Executive Officer